Summary
2-CdA is a deaminase-resistant purine analogue which has shown clinical activity against various hematological tumors, and is currently undergoing clinical phase II trials. The objectives of our study were to determine the activity of 2-CdA against freshly explanted clonogenic cells from non-hematological human tumors and compare this agent with other clinically useful anticancer agents. We also compared short-term (1 hour) and long-term (21–28 days) exposures. For short-term exposure (1-hour), final concentrations were 0.57, 5.7, 57, and 114 ng/ml. Inhibition of tumor specimens was concentration-dependent: 0.57 ng/ml: 1/51 (2%), 5.7 ng/ml: 4/52 (7%), 57 ng/ml: 11/52 (21%), 114 ng/ml: 27/50 (54%). At concentrations ≥57 ng/ml, 2-CdA was as active as cisplatin, doxorubicin, 5-fluorouracil, mitomycin-C, vinblastine, and etoposide. For long-term exposure (21–28 days), final concentrations of 2-CdA were 0.57, 5.7, and 57 ng/ml. At 0.57 ng/ml, 2-CdA was active in 4/54 (7%) specimens [5.7 ng/ml: 13/54 (24%), 57 ng/ml: 40/54 (74%)]. A head-to-head comparison with short-term exposures demonstrated greater activity if the drug exposure time was extended. Using the strategy for testing other standard agents (in vitro dose of 1/10th achievable peak plasma concentration), one would predict clinical response rates for single agent bolus or short-term administration of 2-CdA to be in the neighborhood of 7%. Longer durations of infusion or multiple doses might increase the response rate to about 24%. If higher peak plasma concentrations could be achieved, dose-dependent increases in clinical responses might be achievable. We conclude that 2-CdA is active against clonogenic cells from freshly explanted non-hematological human tumor specimens at high concentrations.
Similar content being viewed by others
References
Carson DA, Kaye J, Wasson DB, Ullmann B, Martin DW, Robins RK, Montgomery JA: Deoxycytidinekinase mediated toxicity of deoxyadenosine analogues toward malig nant human lymphoblastsin vitro and toward murine L 1210 leukemiain vivo. Proc Natl Acad Sci 77:6865–6869, 1980
Beutler E: Cladribine (2-chlorodeoxyadenosine). Lancet 340:952–956, 1992
Carson DA, Wasson DB, Taetle R, Yu A: Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62:737–743, 1983
Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA: Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 75:377–383, 1985
Carrera CJ, Terai C, Lotz M, Curd JG, Piro LD, Beutler E, Carson DA: Potent toxicity of 2-chlorodeoxyadenosine toward human monocytesin vitro andin vivo. J Clin Invest 86:1480–1488, 1990
Carson DA, Wasson DB, Beutler E: Anti-leukemic and immunosuppressive activity of 2-chloro-2.deoxyadenosine. Proc Natl Acad Sci 81:2232–2236, 1984
Piro LD, Carrera CJ, Carson DA, Beutler E: Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322: 1117–1121, 1990
Tallman MS, Hakimian D, Variakojis D, Koslow D, Sisney GA, Rademaker AW, Rose E, Kaul K: A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 80:2203–2209, 1992
Piro LD, Carrera CJ, Beutler E, Carson DA: 2-chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 72:1069–1073, 1988
Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD: 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80:587–592, 1992
Santana V, Mirro JJ, Harwood FC, Cherrie J, Schell M, Kalwinsky D, Blakley RL: A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 9:416–422, 1992
Santana V, Mirro JJ, Kearns C, Schell MJ, Crom W, Blakley RL: 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 10:364–370, 1992
Saven A, Figuerova ML, Piro LD, Beutler E: Complete hematological remissions in chronic myelogenous leukemia (CML) following 2-chlorodeoxyadenosine (2-CdA). (Abstract) Proc Am Soc Clin Onc 11(March):261, 1992
Beutler E, Piro LD, Saven A, Kay AC, McMillan R, Longmire R, Carrera CJ, Morin P, Carson DA: 2-Chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymph 5:1–8, 1991
Liliemark J, Juliusson G: On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans. Cancer Res 51:5570–5572, 1991
Hanauske A-R, Hanauske U, Von Hoff DD: The human tumor cloning assay in cancer research and therapy. Curr Probl Cancer 9:1–50, 1985
Maurer HR, Ali-Osman F: Tumor stem cell cloning in agar-containing capillaries. Naturwiss 68:381–383, 1981
Von Hoff DD, Forseth BJ, Huong M, Buchok JB, Lathan B: Improved plating efficiencies for human tumors cloned in capillary tubes versus Petri dishes. Cancer Res 46:4012–4017, 1986
Hanauske U, Hanauske A-R, Marshall MH, Muggia VA, Von Hoff DD: Biphasic effects of vanadium salts onin vitro tumor colony growth. Int J Cell Cloning 5:170–178, 1987
Hutton JJ, Von Hoff DD: Cytotoxicity of 2-chlorodeoxyadenosine in a human tumor colony-forming assay. Cancer Drug Del 3:115–122, 1986
Larsson R, Fridborg H, Liliemark J, Csoka K, Kristensen J, de la Torre M, Nygren P:In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of human haematological and solid tumours. Eur J Cancer 30A:1022–1026, 1994
Weiss G, Kuhn J, Irvin R, Hardy J, Mooneyham T, Burris III H, Eckardt J, Kalter S, Rodriguez G, Rothenberg M, Von Hoff DD: Phase I trial of 2-chlorodeoxyadenosine (2-CdA) by 120-hour infusion for solid cancers. (Abstract) Proceedings of Asco 12:164, 1993
Weiss GR, Kuhn JG, Rizzo J, Smith LS, Rodriguez GI, Eckardt JR, Burris III HA, Fields S, VanDenBerg K, Von Hoff DD: A phase I and pharmacokinetic study of 2-chlorodeoxyadenosine in patients with solid tumors. Cancer Chemother Pharmacol (in press), 1994
Saven A, Kawasaki H, Carrera CJ, Waltz T, Copeland B, Zyroff J, Kosty M, Carson DA, Beutler E, Piro LD: 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J Clin Oncol 11:671–678, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Depenbrock, H., Wenger, M., Peter, R. et al. Investigation of the comparative effects of 2-chlorodeoxyadenosine on tumor colony forming unitsin vitro . Invest New Drugs 13, 117–123 (1995). https://doi.org/10.1007/BF00872859
Issue Date:
DOI: https://doi.org/10.1007/BF00872859